Skip to main content
AGIOS PHARMACEUTICALS, INC. logo

AGIOS PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · AGIO ISIN · US00847X1046 LEI · 529900ONJHY8EOGYT555 US Manufacturing
Filings indexed 1,228 across all filing types
Latest filing 2026-02-12 Regulatory Filings
Country US United States of America
Listing US AGIO

About AGIOS PHARMACEUTICALS, INC.

https://www.agios.com/

Agios Pharmaceuticals is a commercial-stage biopharmaceutical company that develops therapies for rare and genetically defined diseases. The company leverages its expertise in the science of cellular metabolism to discover and advance new treatments. Its near-term therapeutic focus is on hemolytic and acquired anemias. The company's lead medicine is PYRUKYND® (mitapivat), a first-in-class pyruvate kinase activator. Agios aims to establish a portfolio of disease-modifying therapies that provide long-term effects for patients with significant unmet medical needs.

Recent filings

Filing Released Lang Actions
8-K Filing
Regulatory Filings
2026-02-12 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-09 English
8-K Filing
Regulatory Filings
2026-01-12 English
FORM 4
Director's Dealing
2026-01-07 English
Regulatory Filings 2026
Regulatory Filings
2026-01-05 English
FORM 4
Director's Dealing
2026-01-03 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.